144 related articles for article (PubMed ID: 34794237)
1. Anti-inflammatory and anti-fibrotic effects of modafinil in nonalcoholic liver disease.
Choi S; Kim JA; Li H; Jo SE; Lee H; Kim TH; Kim M; Kim SJ; Suh SH
Biomed Pharmacother; 2021 Dec; 144():112372. PubMed ID: 34794237
[TBL] [Abstract][Full Text] [Related]
2. Modafinil exerts anti-inflammatory and anti-fibrotic effects by upregulating adenosine A
Li H; Kim JA; Jo SE; Lee H; Kim KC; Choi S; Suh SH
Purinergic Signal; 2023 Nov; ():. PubMed ID: 37938538
[TBL] [Abstract][Full Text] [Related]
3. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.
Paka L; Smith DE; Jung D; McCormack S; Zhou P; Duan B; Li JS; Shi J; Hao YJ; Jiang K; Yamin M; Goldberg ID; Narayan P
World J Gastroenterol; 2017 Jun; 23(23):4181-4190. PubMed ID: 28694658
[TBL] [Abstract][Full Text] [Related]
4. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.
Oliván-Viguera A; Valero MS; Murillo MD; Wulff H; García-Otín AL; Arbonés-Mainar JM; Köhler R
PLoS One; 2013; 8(3):e58614. PubMed ID: 23516517
[TBL] [Abstract][Full Text] [Related]
5. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products impair K(Ca)3.1- and K(Ca)2.3-mediated vasodilatation via oxidative stress in rat mesenteric arteries.
Zhao LM; Wang Y; Ma XZ; Wang NP; Deng XL
Pflugers Arch; 2014 Feb; 466(2):307-17. PubMed ID: 23873353
[TBL] [Abstract][Full Text] [Related]
7. Endothelial K
Li JJ; Zhao XY; Wang Y; Xu R; Di XH; Zhang Y; Yang H; Han MZ; Bai RY; Xie L; Pang ZD; Zhang X; Zhang J; Du XJ; Deng XL; Zhang Y; Xie W
Arterioscler Thromb Vasc Biol; 2023 May; 43(5):726-738. PubMed ID: 36951065
[TBL] [Abstract][Full Text] [Related]
8. Laminar shear stress upregulates endothelial Ca²⁺-activated K⁺ channels KCa2.3 and KCa3.1 via a Ca²⁺/calmodulin-dependent protein kinase kinase/Akt/p300 cascade.
Takai J; Santu A; Zheng H; Koh SD; Ohta M; Filimban LM; Lemaître V; Teraoka R; Jo H; Miura H
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H484-93. PubMed ID: 23792675
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.
Brown BM; Shim H; Christophersen P; Wulff H
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():219-240. PubMed ID: 31337271
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of
Kloza M; Baranowska-Kuczko M; Toczek M; Kusaczuk M; Sadowska O; Kasacka I; Kozłowska H
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450834
[TBL] [Abstract][Full Text] [Related]
11. Channelopathy of small- and intermediate-conductance Ca
Nam YW; Downey M; Rahman MA; Cui M; Zhang M
Acta Pharmacol Sin; 2023 Feb; 44(2):259-267. PubMed ID: 35715699
[TBL] [Abstract][Full Text] [Related]
12. Channelopathy-causing mutations in the S
Orfali R; Nam YW; Nguyen HM; Rahman MA; Yang G; Cui M; Wulff H; Zhang M
Cell Calcium; 2022 Mar; 102():102538. PubMed ID: 35030515
[TBL] [Abstract][Full Text] [Related]
13. The influence of DOCA-salt hypertension and chronic administration of the FAAH inhibitor URB597 on K
Kloza M; Baranowska-Kuczko M; Malinowska B; Karpińska O; Harasim-Symbor E; Kasacka I; Kozłowska H
Vascul Pharmacol; 2017 Dec; 99():65-73. PubMed ID: 29038048
[TBL] [Abstract][Full Text] [Related]
14. Thioacetamide potentiates high cholesterol and high fat diet induced steato-hepatitic changes in livers of C57BL/6J mice: A novel eight weeks model of fibrosing NASH.
Sharma L; Gupta D; Abdullah ST
Toxicol Lett; 2019 Apr; 304():21-29. PubMed ID: 30625377
[TBL] [Abstract][Full Text] [Related]
15. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.
Wulff H; Köhler R
J Cardiovasc Pharmacol; 2013 Feb; 61(2):102-12. PubMed ID: 23107876
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary hypertension in wild type mice and animals with genetic deficit in KCa2.3 and KCa3.1 channels.
Wandall-Frostholm C; Skaarup LM; Sadda V; Nielsen G; Hedegaard ER; Mogensen S; Köhler R; Simonsen U
PLoS One; 2014; 9(5):e97687. PubMed ID: 24858807
[TBL] [Abstract][Full Text] [Related]
17. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
Wulff H; Kolski-Andreaco A; Sankaranarayanan A; Sabatier JM; Shakkottai V
Curr Med Chem; 2007; 14(13):1437-57. PubMed ID: 17584055
[TBL] [Abstract][Full Text] [Related]
18. Benzoquinone derivatives with antioxidant activity inhibit activated hepatic stellate cells and attenuate liver fibrosis in TAA-induced mice.
Miao Y; Wu Y; Jin Y; Lei M; Nan J; Wu X
Chem Biol Interact; 2020 Feb; 317():108945. PubMed ID: 31935363
[TBL] [Abstract][Full Text] [Related]
19. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.
Hasenau AL; Nielsen G; Morisseau C; Hammock BD; Wulff H; Köhler R
Acta Physiol (Oxf); 2011 Sep; 203(1):117-26. PubMed ID: 21362152
[TBL] [Abstract][Full Text] [Related]
20. Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery.
Grgic I; Kaistha BP; Hoyer J; Köhler R
Br J Pharmacol; 2009 Jun; 157(4):509-26. PubMed ID: 19302590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
